TWO QUALITIES AVAILABLE

IMATINIB MESILATE (CAS 220127-57-1) is a tyrosine-kinase inhibitor, which is used in the treatment of multiple cancers, most notably Philadelphia chromo-some-positive (Ph+) chronic myelogenous leukemia (CML). It is on WHO’s “List of Essential Drugs."

MARKET INFORMATION

Originator: NOVARTIS
Originator product: GLEEVEC®/GLIVEC^®
Core patent exclusivity expired in December 2015

YOUR ADVANTAGES

FDA-approved, WC available
EU-GMP available
Two qualities available (lower quality with higher impurities but still following the EP draft)

^{This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.}